Market Closed -
Nasdaq
21:00:00 09/05/2024 BST
|
5-day change
|
1st Jan Change
|
5.41
USD
|
-5.17%
|
|
+0.74%
|
+43.88%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
186.6
|
238.6
|
173.2
|
174.1
|
206
|
297.4
|
-
|
-
|
Enterprise Value (EV)
1 |
186.6
|
196.7
|
107.7
|
115.3
|
206
|
376.4
|
365.1
|
297.4
|
P/E ratio
|
-4.04
x
|
-9.65
x
|
-6.07
x
|
-5.7
x
|
-4.13
x
|
-7.34
x
|
-55.5
x
|
4.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
659
x
|
997
x
|
907
x
|
2,662
x
|
-
|
11.8
x
|
3.63
x
|
1.84
x
|
EV / Revenue
|
659
x
|
822
x
|
564
x
|
1,763
x
|
-
|
15
x
|
4.46
x
|
1.84
x
|
EV / EBITDA
|
-8,913,104
x
|
-7,259,375
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-12.4
x
|
-8.91
x
|
-4.77
x
|
-4.69
x
|
-
|
-7.99
x
|
-32.4
x
|
-
|
FCF Yield
|
-8.09%
|
-11.2%
|
-21%
|
-21.3%
|
-
|
-12.5%
|
-3.09%
|
-
|
Price to Book
|
-
|
4.8
x
|
2.76
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
25,631
|
32,111
|
38,065
|
41,260
|
54,790
|
54,981
|
-
|
-
|
Reference price
2 |
7.280
|
7.430
|
4.550
|
4.220
|
3.760
|
5.410
|
5.410
|
5.410
|
Announcement Date
|
16/03/20
|
30/03/21
|
29/03/22
|
30/03/23
|
12/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.2833
|
0.2392
|
0.1909
|
0.0654
|
-
|
25.16
|
81.93
|
162
|
EBITDA
|
-20.93
|
-27.09
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-21.01
|
-27.22
|
-29.44
|
-30.62
|
-48.96
|
-40.22
|
2.757
|
72.58
|
Operating Margin
|
-7,416.2%
|
-11,378.49%
|
-15,417.19%
|
-46,818.48%
|
-
|
-159.87%
|
3.37%
|
44.81%
|
Earnings before Tax (EBT)
1 |
-
|
-27.2
|
-29.46
|
-30.29
|
-46.34
|
-38.74
|
4.296
|
74.6
|
Net income
1 |
-43.54
|
-22.03
|
-28.21
|
-29.7
|
-46.34
|
-45.03
|
6.706
|
85.36
|
Net margin
|
-15,368.97%
|
-9,207.74%
|
-14,774.4%
|
-45,408.52%
|
-
|
-178.99%
|
8.19%
|
52.7%
|
EPS
2 |
-1.800
|
-0.7700
|
-0.7500
|
-0.7400
|
-0.9100
|
-0.7375
|
-0.0975
|
1.150
|
Free Cash Flow
1 |
-15.09
|
-22.08
|
-22.58
|
-24.58
|
-
|
-47.13
|
-11.29
|
-
|
FCF margin
|
-5,326.58%
|
-9,229.73%
|
-11,825.99%
|
-37,572.37%
|
-
|
-187.34%
|
-13.78%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/03/20
|
30/03/21
|
29/03/22
|
30/03/23
|
12/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.0564
|
0.00764
|
0.0212
|
0.00682
|
0.0297
|
-
|
-
|
-
|
-
|
-
|
1.674
|
7.127
|
16.36
|
12
|
15
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.78
|
-7.032
|
-8.24
|
-6.962
|
-8.389
|
-11.02
|
-11.8
|
-10.47
|
-15.67
|
-15.89
|
-15.2
|
-9.368
|
-0.127
|
-8.72
|
-6.9
|
Operating Margin
|
-13,794.18%
|
-92,046.6%
|
-38,778.59%
|
-102,081.09%
|
-28,246.57%
|
-
|
-
|
-
|
-
|
-
|
-907.61%
|
-131.44%
|
-0.78%
|
-72.67%
|
-46%
|
Earnings before Tax (EBT)
1 |
-7.791
|
-7.034
|
-8.19
|
-6.854
|
-8.209
|
-10.57
|
-11.27
|
-9.744
|
-14.75
|
-15.86
|
-14.83
|
-8.999
|
0.2427
|
-8.527
|
-6.707
|
Net income
1 |
-7.791
|
-7.034
|
-7.605
|
-6.854
|
-8.209
|
-10.57
|
-11.27
|
-9.744
|
-14.75
|
-14.47
|
-14.83
|
-8.999
|
0.2427
|
-8.527
|
-6.707
|
Net margin
|
-13,813.81%
|
-92,070.55%
|
-35,787.48%
|
-100,494.43%
|
-27,639.56%
|
-
|
-
|
-
|
-
|
-
|
-885.53%
|
-126.26%
|
1.48%
|
-71.06%
|
-44.71%
|
EPS
2 |
-0.2000
|
-0.1800
|
-0.1900
|
-0.1700
|
-0.2000
|
-0.2400
|
-0.2500
|
-0.1700
|
-0.2600
|
-0.2500
|
-0.2600
|
-0.1725
|
-0.0575
|
-0.1100
|
-0.0900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/03/22
|
12/05/22
|
11/08/22
|
10/11/22
|
30/03/23
|
15/05/23
|
08/08/23
|
14/11/23
|
12/03/24
|
09/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
79
|
67.7
|
-
|
Net Cash position
1 |
-
|
41.9
|
65.5
|
58.8
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-15.1
|
-22.1
|
-22.6
|
-24.6
|
-
|
-47.1
|
-11.3
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
1.550
|
1.650
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.11
|
1.43
|
0.22
|
-
|
0.02
|
0.02
|
-
|
Capex / Sales
|
-
|
47.08%
|
746.48%
|
335.36%
|
-
|
0.08%
|
0.02%
|
-
|
Announcement Date
|
16/03/20
|
30/03/21
|
29/03/22
|
30/03/23
|
12/03/24
|
-
|
-
|
-
|
Last Close Price
5.41
USD Average target price
13
USD Spread / Average Target +140.30% Consensus |
1st Jan change
|
Capi.
|
---|
| +43.88% | 297M | | +8.33% | 72.94B | | -10.36% | 5.07B | | +51.87% | 4.78B | | +4.51% | 3.9B | | -14.26% | 2.56B | | +20.25% | 2.42B | | -23.94% | 2.39B | | +20.02% | 2.18B | | +3.66% | 1.65B |
Specialty & Advanced Pharmaceuticals
|